Umeda M, Katoh M, Niitsu N, Takata M, Katoh M, Shikoshi K
First Department of Internal Medicine, Toho University School of Medicine.
Nihon Ronen Igakkai Zasshi. 1994 Dec;31(12):969-74. doi: 10.3143/geriatrics.31.969.
VCAP chemotherapy combined with natural interferon-alpha (HBLI) was performed on elderly patients over 65 year with multiple myeloma (MM), and its clinical effects were compared with those of VCAP chemotherapy without HLBI on elderly MM and also with those of HLBI-VCAP and VCAP combination therapy on non-elderly MM. Sixteen elderly and 21 non-elderly patients received HLBI-VCAP combination therapy, whereas 12 elderly and 21 non-elderly patients were treated with VCAP chemotherapy alone. The remission rate (CR+PR) was 81% for the elderly HLBI-VCAP group, 58% for the elderly VCAP group, 90% for the non-elderly HLBI-VCAP group, and 76% for the non-elderly VCAP group. While the median survival time was 54 months for the elderly HLBI-VCAP group and 13.5 months for the elderly VCAP group, it was 70 months for non-elderly HLBI-VCAP group and 34.5 months for the non-elderly VCAP group. The survival time in the elderly HLBI-VCAP group was significantly longer than that in the elderly VCAP group. Therefore, improvement of survival in cases treated by interferon was much better in the elderly group than in the non-elderly group. These results indicate that HLBI-VCAP combination therapy is beneficial for the treatment of elderly MM.
对65岁以上的老年多发性骨髓瘤（MM）患者采用VCAP化疗联合天然α干扰素（HBLI）进行治疗，并将其临床疗效与未使用HLBI的VCAP化疗对老年MM患者的疗效以及HLBI-VCAP和VCAP联合治疗对非老年MM患者的疗效进行比较。16名老年患者和21名非老年患者接受了HLBI-VCAP联合治疗，而12名老年患者和21名非老年患者仅接受了VCAP化疗。老年HLBI-VCAP组的缓解率（CR+PR）为81%，老年VCAP组为58%，非老年HLBI-VCAP组为90%，非老年VCAP组为76%。老年HLBI-VCAP组的中位生存时间为54个月，老年VCAP组为13.5个月，非老年HLBI-VCAP组为70个月，非老年VCAP组为34.5个月。老年HLBI-VCAP组的生存时间明显长于老年VCAP组。因此，干扰素治疗病例的老年组生存改善比非老年组好得多。这些结果表明，HLBI-VCAP联合治疗对老年MM的治疗有益。
